This site is intended for healthcare professionals

Gamida Cell presents efficacy and safety results of phase III study of omidubicel for hematologic malignancies at the 2021 TCT meetings of ASTCT and CIBMTR.

Read time: 2 mins
Last updated:16th Feb 2021
Published:16th Feb 2021
Condition: Haematopoietic Stem Cell Transplantation
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest